Neovascular endothelium membranes

Neovascular endothelium membranes refer to the cell membranes of newly formed, pathological blood vessels that arise during angiogenesis in diseases such as cancer and age-related macular degeneration (AMD) [1][2]. Unlike mature, stable vasculature, the neovascular endothelium is characterized by rapid proliferation, high permeability, and the expression of specific markers like phosphatidylserine, integrins, and vascular endothelial growth factor receptors (VEGFRs) [2][3]. These membranes serve as a critical therapeutic target for two main classes of drugs: anti-angiogenic agents, which inhibit the signaling pathways (like VEGF) that drive vessel growth, and vascular disrupting agents (VDAs), which selectively destroy existing neovessels by inducing endothelial cell shape changes and subsequent vessel collapse [4][5]. Targeting these membranes allows for the selective treatment of tumors or retinal lesions while sparing healthy, quiescent vasculature [4]. However, because this target is a complex cellular structure rather than a single molecule, therapeutic strategies often involve multi-target approaches or the use of specific surface markers for drug delivery [1][3].

Other names

Neovascular endotheliumTumor neovasculatureChoroidal neovascular membranesCNVMPathological angiogenesis

Drugs targeting neovascular endothelium membranes primarily work through two mechanisms: vascular disruption and inhibition of angiogenesis. Vascular disrupting agents (VDAs) like fosbretabulin target the cytoskeleton of endothelial cells in newly formed vessels, causing them to change shape and lead to rapid vessel occlusion and necrosis [4]. Anti-angiogenic agents, such as anti-VEGF antibodies, bind to growth factors or their receptors on the endothelial surface to inhibit the signaling pathways that drive vessel proliferation and leakage [5]. Additionally, some agents target specific lipids like phosphatidylserine that are selectively exposed on the outer leaflet of neovascular membranes [2][3].